Consistent with these results, three months of daily ip injections of nobiletin (10 and 30 mg/kg) starting at 6 months of age in the 3 × FAD model (AD-linked mutations in APP, PS1, and tau) resulted in an improvement in memory on multiple tests and a reduction in soluble Aβ levels, as well as reactive oxygen species (ROS) in the mice treated with 30 mg/kg [43]. The gene discussed is MAPT; the disease is Alzheimer disease.